score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability - High	Ipilimumab	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498												0				 mutations per Mb		MEL-IPI_Pat32		
Investigate Actionability - High		Guideline		Somatic Variant	ABL1	Missense	p.S420F	0.2687	67.0	0.0	0.0								Investigate Actionability - High	Dasatinib	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf						0				ABL1 p.S420F (Missense)		MEL-IPI_Pat32	MEL-IPI_Pat32-Tumor-SM-53U3T	MEL-IPI_Pat32-Normal-SM-53U67
Investigate Actionability - High		Clinical evidence		Copy Number	BRAF	Amplification				0.0	0.0								Investigate Actionability - High	Vemurafenib	Targeted therapy	Amplification of BRAF may predict resistance to RAF inhibition.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631						0				BRAF Amplification		MEL-IPI_Pat32	MEL-IPI_Pat32-Tumor-SM-53U3T	
Investigate Actionability - High			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0														Investigate Actionability - High	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		MEL-IPI_Pat32	MEL-IPI_Pat32-Tumor-SM-53U3T	
Investigate Actionability - Low	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Insertion	p.599_599T>TT	0.6717	399.0	0.0	0.0		Investigate Actionability - Low	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - Low	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - Low	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.599_599T>TT (Insertion)	1.0	MEL-IPI_Pat32	MEL-IPI_Pat32-Tumor-SM-53U3T	MEL-IPI_Pat32-Normal-SM-53U67
Investigate Actionability - Low	FDA-Approved			Somatic Variant	TSC2	Missense	p.T1154S	0.4208	259.0	0.0	0.0		Investigate Actionability - Low	Everolimus	Targeted Therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Everolimus [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf												0				TSC2 p.T1154S (Missense)		MEL-IPI_Pat32	MEL-IPI_Pat32-Tumor-SM-53U3T	MEL-IPI_Pat32-Normal-SM-53U67
Investigate Actionability - Low	FDA-Approved			Somatic Variant	TSC2	Missense	p.T1154I	0.4125	257.0	8e-06	0.0		Investigate Actionability - Low	Everolimus	Targeted Therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Everolimus [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2012.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf												0				TSC2 p.T1154I (Missense)		MEL-IPI_Pat32	MEL-IPI_Pat32-Tumor-SM-53U3T	MEL-IPI_Pat32-Normal-SM-53U67
Investigate Actionability - Low	Preclinical			Copy Number	AURKB	Deletion				0.0	0.0		Investigate Actionability - Low	Barasertib	Targeted therapy	MYC amplified small cell lung cancer	Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322.	https://doi.org/10.1158/1535-7163.MCT-16-0298												0				AURKB Deletion		MEL-IPI_Pat32	MEL-IPI_Pat32-Tumor-SM-53U3T	
Biologically Relevant				Copy Number	ESRP1	Amplification				0.0	0.0																			0				ESRP1 Amplification		MEL-IPI_Pat32	MEL-IPI_Pat32-Tumor-SM-53U3T	
Biologically Relevant				Microsatellite Stability	Supporting variants		ESRP1 Amplification, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																							0				Supporting variants: ESRP1 Amplification, PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat32		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.762																							0				COSMIC Signature 7 (76%)		MEL-IPI_Pat32		
